<H1>Chapter DOI: 10.1208/aapsj070109<br/>Cited-By Count: 251</H1><table border="1" width="30%"><tr><td>Total References</td><td>157</td></tr><tr><td>Springer references</td><td>14</td></tr><tr><td>Non Springer references</td><td>143</td></tr><tr><td>BibStructured Count</td><td width="10%">155</td></tr><tr><td>BibUnstructured Count</td><td width="10%">2</td></tr><tr><td>DOI already available in SpringerLink</td><td>108</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>20</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>3</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>1</td></tr><tr><td>DOI Obtained For Non Springer</td><td>22</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>23</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Crooke ST. An overview of progress in antisense therapeutics.<Emphasis Type="Italic">Antisense Nucleic Acid Drug Dev</Emphasis>. 1998;8:115&#8211;122.</td><td><a href=http://dx.doi.org/10.1089/oli.1.1998.8.115>10.1089/oli.1.1998.8.115</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, FirstPage, Year, VolumeID</td><td>CrossRef</td></tr><tr><td>CR2</td><td>BibArticle</td><td>Stull RA, Szoka FC Jr. Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1995;12:465&#8211;483.</td><td><a href=http://dx.doi.org/10.1023/A:1016281324761>10.1023/A:1016281324761</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR3</td><td>BibArticle</td><td>Patil SD, Burgess DJ. DNA-based Biopharmaceuticals: therapeutics for the 21st Century.<Emphasis Type="Italic">AAPS Newsmagazine</Emphasis> 2003;6(12):27.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Baker BF. The role of antisense oligonucleotides in the wave of genomic information.<Emphasis Type="Italic">Nucleosides Nucleotides Acids</Emphasis>, 2001;20(4&#8211;7):397&#8211;399.</td><td><a href=http://dx.doi.org/10.1081/NCN-100002313>10.1081/NCN-100002313</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibArticle</td><td>Van Ommen GJB, Bakker E, Den Dunnen JT. The human genome project and the future of diagnostics, treatment, and prevention.<Emphasis Type="Italic">Lancet</Emphasis>. 1999;354(suppl 1):5&#8211;10.</td><td><a href=http://dx.doi.org/10.1016/S0140-6736(99)90241-6>10.1016/S0140-6736(99)90241-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Uherek C, Wels W. DNA-carrier proteins for targeted gene delivery.<Emphasis Type="Italic">Adv Drug Deliv Rev</Emphasis>. 2000;44(2&#8211;3):153&#8211;166.</td><td><a href=http://dx.doi.org/10.1016/S0169-409X(00)00092-2>10.1016/S0169-409X(00)00092-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Johnston SA, Talaat AM, McGuire MJ. Genetic Immunization What's in a Name?<Emphasis Type="Italic">Arch Med Res</Emphasis>. 2002;33:325&#8211;329.</td><td><a href=http://dx.doi.org/10.1016/S0188-4409(02)00383-1>10.1016/S0188-4409(02)00383-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Denny WA. Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy).<Emphasis Type="Italic">J Biomed Biotechnol</Emphasis>. 2003;1:48&#8211;70.</td><td><a href=http://dx.doi.org/10.1155/S1110724303209098>10.1155/S1110724303209098</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR9</td><td>BibArticle</td><td>Denny WA, Wilson WR. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies.<Emphasis Type="Italic">J Pharm Pharmacol</Emphasis> 1998;50:387&#8211;394.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1111/j.2042-7158.1998.tb06878.x>10.1111/j.2042-7158.1998.tb06878.x</a></td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, VolumeID, Author_FamilyName_1, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Connors TA. The choice of prodrugs for gene directed enzyme produrg therapy of cancer.<Emphasis Type="Italic">Gene Ther</Emphasis> 1995;2:702&#8211;709.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR11</td><td>BibArticle</td><td>Bentires-Alj M, Hellin A-C, Lechanteur C, et al. Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis.<Emphasis Type="Italic">Cancer Gene Ther</Emphasis>. 2000;7:20&#8211;26.</td><td><a href=http://dx.doi.org/10.1038/sj.cgt.7700093>10.1038/sj.cgt.7700093</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR12</td><td>BibArticle</td><td>Anderson WF. Prospects for human gene therapy.<Emphasis Type="Italic">Science</Emphasis>. 1984;226:401&#8211;409.</td><td><a href=http://dx.doi.org/10.1126/science.6093246>10.1126/science.6093246</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR13</td><td>BibArticle</td><td>Fitzsimons HL, Bland RJ, During MJ. Promoters and regulatory elements that improve adeno-associated virus transgene expression in the brain.<Emphasis Type="Italic">Methods</Emphasis>. 2002;28(2):227&#8211;236.</td><td><a href=http://dx.doi.org/10.1016/S1046-2023(02)00227-X>10.1016/S1046-2023(02)00227-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR14</td><td>BibArticle</td><td>Walther W, Stein U. Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting.<Emphasis Type="Italic">Journal of Molecular Medicine (Berlin)</Emphasis>. 1996;74:379&#8211;392.</td><td><a href=http://dx.doi.org/10.1007/BF00210632>10.1007/BF00210632</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, Author_FamilyName_1, VolumeID, JournalTitle, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR15</td><td>BibArticle</td><td>Qin L, Ding Y, Pahud DR, Chang E, Imperiale MJ, Bromberg JS. Promoter attenuation in gene therapy: interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression.<Emphasis Type="Italic">Hum Gene Ther</Emphasis>. 1997;8:2019&#8211;2029.</td><td><a href=http://dx.doi.org/10.1089/hum.1997.8.17-2019>10.1089/hum.1997.8.17-2019</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR16</td><td>BibArticle</td><td>Paillard F. Promoter attenuation in gene therapy: causes and remedies.<Emphasis Type="Italic">Hum Gene Ther</Emphasis>. 1997;8:2009&#8211;2010.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR17</td><td>BibArticle</td><td>Weeratna RD, Wu T, Etler SM, Zhang L, Davis HL. Designing gene therapy vectors: avoiding immune responses by using tissue-specific promoters.<Emphasis Type="Italic">Gene Ther</Emphasis>. 2001;8:1872&#8211;1878.</td><td><a href=http://dx.doi.org/10.1038/sj.gt.3301602>10.1038/sj.gt.3301602</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR18</td><td>BibArticle</td><td>Greco O, Marples B, Dachs GU, Williams KJ, Patterson AV, Scott SD. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation.<Emphasis Type="Italic">Gene Ther</Emphasis> 2002;9:1403&#8211;1411.</td><td><a href=http://dx.doi.org/10.1038/sj.gt.3301823>10.1038/sj.gt.3301823</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR19</td><td>BibArticle</td><td>Anderson WF. Human gene therapy.<Emphasis Type="Italic">Nature (London)</Emphasis>. 1998;392(suppl 6679):25&#8211;30.</td><td><a href=http://dx.doi.org/10.1126/science.1589762>10.1126/science.1589762</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR20</td><td>BibArticle</td><td>Vorburger SA, Hunt KK. Adenovirall gene therapy.<Emphasis Type="Italic">Oncologist</Emphasis>. 2002;7:46&#8211;59.</td><td><a href=http://dx.doi.org/10.1634/theoncologist.7-1-46>10.1634/theoncologist.7-1-46</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR21</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>China</span> <span style='background:#DDDDDD'>OKs Gene Therapy Drug</span></span></aug>. <i>Genetic Engineering News</i>. <span style='background:#66FF66'>2003</span>: <span style='background:#D279FF'>6</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR22</td><td>BibArticle</td><td>Galanis E, Russell S. Cancer gene therapy clinical trials: lessons for the future.<Emphasis Type="Italic">Br J Cancer</Emphasis> 2001;85:1432&#8211;1436.</td><td><a href=http://dx.doi.org/10.1054/bjoc.2001.2129>10.1054/bjoc.2001.2129</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR23</td><td>BibArticle</td><td>Mulherkar R. Gene therapy for cancer.<Emphasis Type="Italic">Curr Sci.</Emphasis> 2001;81:555&#8211;560.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR24</td><td>BibArticle</td><td>Baekelandt V, De Strooper B, Nuttin B, Debyser Z. Gene therapeutic strategies for neurodegenerative diseases.<Emphasis Type="Italic">Curr Opin Mol Ther</Emphasis>. 2000;2:540&#8211;554.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR25</td><td>BibArticle</td><td>Bunnell BA, Morgan RA. Gene therapy for HIV infection.<Emphasis Type="Italic">Drugs Today</Emphasis> 1996;32:209&#8211;224.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/0471223875.ch11>10.1002/0471223875.ch11</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR26</td><td>BibArticle</td><td>Horner AA, Van Uden JH, Zubeldia JM, Broide D, Raz E. DNA-based immunotherapeutics for the treatment of allergic disease.<Emphasis Type="Italic">Immunol Rev.</Emphasis> 2001;179:102&#8211;118.</td><td><a href=http://dx.doi.org/10.1034/j.1600-065X.2001.790111.x>10.1034/j.1600-065X.2001.790111.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR27</td><td>BibArticle</td><td>Crooke ST. Molecular mechanisms of action of antisense drugs.<Emphasis Type="Italic">Biochim Biophys Acta</Emphasis>. 1999;1489:31&#8211;43.</td><td><a href=http://dx.doi.org/10.1016/S0167-4781(99)00148-7>10.1016/S0167-4781(99)00148-7</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, FirstPage, ArticleTitle, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR28</td><td>BibArticle</td><td>Crooke ST. Molecular mechanisms of antisense drugs: human RNase H.<Emphasis Type="Italic">Antisense Nucleic Acid Drug Dev</Emphasis> 1999;9:377&#8211;379.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1089/oli.1.1998.8.133>10.1089/oli.1.1998.8.133</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR29</td><td>BibChapter</td><td>Engels JW, Uhlmann E. Chemistry of Oligonucleotides. In: Malvy C, ed.<Emphasis Type="Italic">Pharmaceutical Aspects of Oligonucleotides</Emphasis>. London, UK: Taylor &amp; Francis Ltd; 2000;35&#8211;78.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.4324/9780203305669>10.4324/9780203305669</a></td><td><b>CrossRef-Web</b></td>
<td>BookTitle, Year</td><td>CrossRef</td></tr><tr><td>CR30</td><td>BibArticle</td><td>Khatsenko O, Morgan R, Truong L, et al. Absorption of antisense oligonucleotides in rat intestine: effect of chemistry and length.<Emphasis Type="Italic">Antisense Nucleic Acid Drug Dev</Emphasis> 2000;10:35&#8211;44.</td><td><a href=http://dx.doi.org/10.1089/oli.1.2000.10.35>10.1089/oli.1.2000.10.35</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>ArticleTitle, Author_FamilyName_2, Author_FamilyName_1, FirstPage, VolumeID, Year</td><td>CrossRef</td></tr><tr><td>CR31</td><td>BibArticle</td><td>Stein CA, Subasinghe C, Shinozuka K, Cohen JS. Physicochemical properties of phosphorothioate oligodeoxynucleotides.<Emphasis Type="Italic">Nucleic Acids Res</Emphasis>. 1988;16:3209&#8211;3221.</td><td><a href=http://dx.doi.org/10.1093/nar/16.8.3209>10.1093/nar/16.8.3209</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR32</td><td>BibArticle</td><td>Matteucci M. Structural modifications toward improved antisense oligonucleotides.<Emphasis Type="Italic">Perspectives in Drug Discovery and Design</Emphasis>. 1996;4(Antisense Therapeutics):1&#8211;16.</td><td><a href=http://dx.doi.org/10.1007/BF02172105>10.1007/BF02172105</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR33</td><td>BibArticle</td><td>Shoji Y, Akhtar S, Periasamy A, Herman B, Juliano RL. Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages.<Emphasis Type="Italic">Nucleic Acids Res.</Emphasis> 1991;19:5543&#8211;5550.</td><td><a href=http://dx.doi.org/10.1093/nar/19.20.5543>10.1093/nar/19.20.5543</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR34</td><td>BibArticle</td><td>Akhtar S. Antisense technology: selection and delivery of optimally acting antisense oligonucleotides.<Emphasis Type="Italic">J Drug Target</Emphasis>. 1998;5:225&#8211;234.</td><td><a href=http://dx.doi.org/10.3109/10611869808995877>10.3109/10611869808995877</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, VolumeID, Year, FirstPage</td><td>CrossRef</td></tr><tr><td>CR35</td><td>BibArticle</td><td>Smith L, Andersen KB, Hovgaard L, Jaroszewski JW. Rational selection of antisense oligonucleotide sequences.<Emphasis Type="Italic">Eur J Pharm Sci</Emphasis>. 2000;11:191&#8211;198.</td><td><a href=http://dx.doi.org/10.1016/S0928-0987(00)00100-7>10.1016/S0928-0987(00)00100-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR36</td><td>BibArticle</td><td>Patil SD, Rhodes DG. Influence of divalent cations on the conformation of phosphorothioate oligodeoxynucleotides: a circular dichroism study.<Emphasis Type="Italic">Nucleic Acids Res</Emphasis>. 2000;28:2439&#8211;2445.</td><td><a href=http://dx.doi.org/10.1093/nar/28.12.2439>10.1093/nar/28.12.2439</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR37</td><td>BibArticle</td><td>Agrawal S, Tan W, Cai Q, Xie X, Zhang R. In vivo pharmacokinetics of phosphorothioate oligonucleotides containing contiguous guanosines.<Emphasis Type="Italic">Antisense Nucleic Acid Drug Dev</Emphasis> 1997;7:245&#8211;249.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR38</td><td>BibArticle</td><td>Akhtar S, Hughes MD, Khan A, et al. The delivery of antisense therapeutics.<Emphasis Type="Italic">Adv Drug Deliv Rev</Emphasis>. 2000;44:3&#8211;21.</td><td><a href=http://dx.doi.org/10.1016/S0169-409X(00)00080-6>10.1016/S0169-409X(00)00080-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR39</td><td>BibArticle</td><td>Crooke ST. Vitravene another piece in the mosaic.<Emphasis Type="Italic">Antisense Nucleic Acid Drug Dev</Emphasis>. 1998;8:vii-v3.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1089/oli.1.1998.8.vii>10.1089/oli.1.1998.8.vii</a></td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, Year, VolumeID, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR40</td><td>BibArticle</td><td>Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer.<Emphasis Type="Italic">Adv Drug Deliv Rev.</Emphasis> 2002;54:715&#8211;758.</td><td><a href=http://dx.doi.org/10.1016/S0169-409X(02)00046-7>10.1016/S0169-409X(02)00046-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR41</td><td>BibArticle</td><td>Aigner A, Juhl H, Malerczyk C, Tkybusch A, Benz CC, Czubayko F. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumor cell proliferation.<Emphasis Type="Italic">Oncogene</Emphasis>. 2001;20:2101&#8211;2111.</td><td><a href=http://dx.doi.org/10.1038/sj.onc.1204305>10.1038/sj.onc.1204305</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR42</td><td>BibArticle</td><td>Zhang L, Gasper WJ, Stass SA, Ioffe OB, Davis MA, Mixson AJ. Angiogenic inhibition mediated by a DNA zyme that targets vascular endothelial growth factor receptor 2.<Emphasis Type="Italic">Cancer Res</Emphasis> 2002;62:5463&#8211;5469.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR43</td><td>BibArticle</td><td>Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics.<Emphasis Type="Italic">Clin Chem.</Emphasis> 1999;45(9):1628&#8211;1650.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR44</td><td>BibArticle</td><td>de Soultrait VR, Lozach P-Y, Altmeyer R, Tarrago-Litvak L, Litvak S, Andreola ML. DNA aptamers derived from HIV-I RNase H inhibitors are strong anti-integrase agents.<Emphasis Type="Italic">J Mol Biol</Emphasis>. 2002;324:195&#8211;203.</td><td><a href=http://dx.doi.org/10.1016/S0022-2836(02)01064-1>10.1016/S0022-2836(02)01064-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR45</td><td>BibArticle</td><td>Chaloin L, Lehmann MJ, Sczakiel G, Restle T. Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1.<Emphasis Type="Italic">Nucleic Acids Res</Emphasis>. 2002;30:4001&#8211;4008.</td><td><a href=http://dx.doi.org/10.1093/nar/gkf522>10.1093/nar/gkf522</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR46</td><td>BibArticle</td><td>Bertrand J-R, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo.<Emphasis Type="Italic">Biochem Biophys Res Commun</Emphasis>. 2002;296:1000&#8211;1004.</td><td><a href=http://dx.doi.org/10.1016/S0006-291X(02)02013-2>10.1016/S0006-291X(02)02013-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR47</td><td>BibArticle</td><td>McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs.<Emphasis Type="Italic">Nat Rev Genet</Emphasis>. 2002;3:737&#8211;747.</td><td><a href=http://dx.doi.org/10.1038/nrg908>10.1038/nrg908</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR48</td><td>BibArticle</td><td>Scherr M, Morgan MA, Eder M. Gene silencing mediated by small interfering RNAs in mammalian cells.<Emphasis Type="Italic">Curr Med Chem</Emphasis>. 2003;10:245&#8211;256.</td><td><a href=http://dx.doi.org/10.2174/0929867033368493>10.2174/0929867033368493</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>FirstPage, VolumeID, Year, ArticleTitle, Author_FamilyName_1, Author_FamilyName_2</td><td>CrossRef</td></tr><tr><td>CR49</td><td>BibArticle</td><td>Kurreck J. Antisense technologies: improvement through movel chemical modifications.<Emphasis Type="Italic">Eur J Biochem</Emphasis>. 2003;270:1628&#8211;1644.</td><td><a href=http://dx.doi.org/10.1046/j.1432-1033.2003.03555.x>10.1046/j.1432-1033.2003.03555.x</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR50</td><td>BibArticle</td><td>Martinez MA, Gutierrez A, Armand-Ugon M, et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication.<Emphasis Type="Italic">AIDS</Emphasis>. 2002;16(18):2385&#8211;2390.</td><td><a href=http://dx.doi.org/10.1097/00002030-200212060-00002>10.1097/00002030-200212060-00002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR51</td><td>BibArticle</td><td>Zamore PD, Aronin N. siRNAs knock down hepatitis.<Emphasis Type="Italic">Nat Med</Emphasis>. 2003;9(3):266&#8211;267.</td><td><a href=http://dx.doi.org/10.1038/nm0303-266>10.1038/nm0303-266</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR52</td><td>BibArticle</td><td>Ge Q, McManus MT, Nguyen T, et al. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2003;100:2718&#8211;2723.</td><td><a href=http://dx.doi.org/10.1073/pnas.0437841100>10.1073/pnas.0437841100</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR53</td><td>BibArticle</td><td>Bennett RM. As nature intended? The uptake of DNA and oligonucleotides by eukaryotic cells.<Emphasis Type="Italic">Antisense Res Dev</Emphasis>. 1993;3:235&#8211;241.</td><td><a href=http://dx.doi.org/10.1089/ard.1993.3.235>10.1089/ard.1993.3.235</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, Year, VolumeID, FirstPage</td><td>CrossRef</td></tr><tr><td>CR54</td><td>BibArticle</td><td>Le Doan T. Cell binding and internalisation of oligonucleotides.<Emphasis Type="Italic">S.T.P. Pharma Sciences</Emphasis>. 2001;11:75&#8211;82.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR55</td><td>BibArticle</td><td>Crooke ST. Delivery of oligonucleotides and polynucleotides.<Emphasis Type="Italic">J Drug Target</Emphasis>. 1995;3:185&#8211;190.</td><td><a href=http://dx.doi.org/10.3109/10611869509015944>10.3109/10611869509015944</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR56</td><td>BibArticle</td><td>Hughes MD, Hussain M, Nawaz Q, Sayyed P, Akhtar S. The cellular delivery of antisense oligonucleotides and ribozymes.<Emphasis Type="Italic">Drug Discov Today</Emphasis>. 2001;6:303&#8211;315.</td><td><a href=http://dx.doi.org/10.1016/S1359-6446(00)00326-3>10.1016/S1359-6446(00)00326-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR57</td><td>BibArticle</td><td>Liu F, Huang L. Development of non-viral vectors for systemic gene delivery.<Emphasis Type="Italic">J Control Release</Emphasis>. 2002;78(1&#8211;3):259&#8211;266.</td><td><a href=http://dx.doi.org/10.1016/S0168-3659(01)00494-1>10.1016/S0168-3659(01)00494-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR58</td><td>BibArticle</td><td>Akhtar S, Juliano RL. Cellular uptake and intracellular fate of antisense oligonucleotides.<Emphasis Type="Italic">Trends Cell Biol</Emphasis>. 1992;2:139&#8211;144.</td><td><a href=http://dx.doi.org/10.1016/0962-8924(92)90100-2>10.1016/0962-8924(92)90100-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR59</td><td>BibArticle</td><td>Wu-Pong S. Alternative interpretations of the oligonucleotide transport literature: insights from nature.<Emphasis Type="Italic">Adv Drug Deliv Rev</Emphasis>. 2000;44:59&#8211;70.</td><td><a href=http://dx.doi.org/10.1016/S0169-409X(00)00084-3>10.1016/S0169-409X(00)00084-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR60</td><td>BibArticle</td><td>Holmes AR, Dohrman AF, Ellison AR, Gonez KK, Gruenert DC. Intracellular compartmentalization of DNA fragments in cultured airway epithelial cells mediated by cationic lipids.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1999;16:1020&#8211;1025.</td><td><a href=http://dx.doi.org/10.1023/A:1018927531003>10.1023/A:1018927531003</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR61</td><td>BibArticle</td><td>Kamiya H, Tsuchiya H, Yamazaki J, Harashima H. Intracellular trafficking and transgene expression of viral and non-viral gene vectors.<Emphasis Type="Italic">Adv Drug Deliv Rev</Emphasis>. 2001;52:153&#8211;164.</td><td><a href=http://dx.doi.org/10.1016/S0169-409X(01)00216-2>10.1016/S0169-409X(01)00216-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR62</td><td>BibArticle</td><td>Tachibana R, Harashima H, Shinohara Y, Kiwada H. Quantitative studies on the nuclear transport of plasmid DNA and gene expression employing nonviral vectors.<Emphasis Type="Italic">Adv Drug Deliv Rev</Emphasis>. 2001;52:219&#8211;226.</td><td><a href=http://dx.doi.org/10.1016/S0169-409X(01)00211-3>10.1016/S0169-409X(01)00211-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR63</td><td>BibArticle</td><td>Brown MD, Schatzlein AG, Uchegbu IF. Gene delivery with synthetic (non viral) carriers.<Emphasis Type="Italic">Int J Pharm</Emphasis>. 2001;229(1&#8211;2):1&#8211;21.</td><td><a href=http://dx.doi.org/10.1016/S0378-5173(01)00861-4>10.1016/S0378-5173(01)00861-4</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR64</td><td>BibArticle</td><td>Luo D, Saltzman WM. Synthetic DNA delivery systems.<Emphasis Type="Italic">Nat Biotechnol.</Emphasis>. 2000;18:33&#8211;37.</td><td><a href=http://dx.doi.org/10.1038/71889>10.1038/71889</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR65</td><td>BibArticle</td><td>Agrawal S, Zhang R. Pharmacokinetics of oligonucleotides.<Emphasis Type="Italic">Ciba Foundation Symposium</Emphasis>. 1997;209(Oligonucleotides as Therapeutic Agents):60&#8211;78.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1002/9780470515396.ch6>10.1002/9780470515396.ch6</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Author_FamilyName_1, FirstPage</td><td>CrossRef</td></tr><tr><td>CR66</td><td>BibArticle</td><td>Yu RZ, Geary RS, Leeds JM, et al. Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of ha-ras encapsulated in stealth liposomes.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1999;16:1309&#8211;1315.</td><td><a href=http://dx.doi.org/10.1023/A:1014822219133>10.1023/A:1014822219133</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR67</td><td>BibArticle</td><td>Tam P, Monck M, Lee D, et al. Stabilized plasmid-lipid particles for systemic gene therapy.<Emphasis Type="Italic">Gene Ther</Emphasis>. 2000;7:1867&#8211;1874.</td><td><a href=http://dx.doi.org/10.1038/sj.gt.3301308>10.1038/sj.gt.3301308</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR68</td><td>BibArticle</td><td>Kunisawa J, Nakagawa S, Mayumi T. Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development.<Emphasis Type="Italic">Adv Drug Deliv Rev</Emphasis>. 2001;52:177&#8211;186.</td><td><a href=http://dx.doi.org/10.1016/S0169-409X(01)00214-9>10.1016/S0169-409X(01)00214-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR69</td><td>BibArticle</td><td>Hope MJ, Mui B, Ansell S, Ahkong QF. Cationic lipids, phosphatidylethanolamine and the intracellular delivery of polymeric, nucleic acid-based drugs.<Emphasis Type="Italic">Mol Membr Biol.</Emphasis>. 1998;15:1&#8211;14.</td><td><a href=http://dx.doi.org/10.3109/09687689809027512>10.3109/09687689809027512</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR70</td><td>BibArticle</td><td>Jaaskelainen I, Moenkkoenen J, Urtti A. Oligonucleotide-cationic liposome interactions. A physicochemical study.<Emphasis Type="Italic">Biochim Biophys Acta</Emphasis>. 1994;1195:115&#8211;123.</td><td><a href=http://dx.doi.org/10.1016/0005-2736(94)90017-5>10.1016/0005-2736(94)90017-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR71</td><td>BibArticle</td><td>Jaaskelainen I, Sternberg B, Monkkonen J, Urtti A. Physicochemical and morphological properties of complexes made of cationic liposomes and oligonucleotides.<Emphasis Type="Italic">Int J Pharm</Emphasis>. 1998; 167(1&#8211;2):191&#8211;203.</td><td><a href=http://dx.doi.org/10.1016/S0378-5173(98)00067-2>10.1016/S0378-5173(98)00067-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR72</td><td>BibArticle</td><td>Monnard P-A, Oberholzer T, Luisi P. Entrapment of nucleic acids in liposomes.<Emphasis Type="Italic">Biochim Biophys Acta</Emphasis>. 1997;1329:39&#8211;50.</td><td><a href=http://dx.doi.org/10.1016/S0005-2736(97)00066-7>10.1016/S0005-2736(97)00066-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR73</td><td>BibArticle</td><td>McAllister DV, Allen MG, Prausnitz MR. Microfabricated microneedles for gene and drug delivery.<Emphasis Type="Italic">Annu Rev Biomed Eng</Emphasis>. 2000;2:289&#8211;313.</td><td><a href=http://dx.doi.org/10.1146/annurev.bioeng.2.1.289>10.1146/annurev.bioeng.2.1.289</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR74</td><td>BibArticle</td><td>Regnier V, Tahiri A, Andre N, Lemaitre M, Le Doan T, Preat V. Electroporation-mediated delivery of 3&#8242;-protected phosphodiester oligodeoxynucleotides to the skin.<Emphasis Type="Italic">J Control Release</Emphasis>. 2000;67(2&#8211;3):337&#8211;346.</td><td><a href=http://dx.doi.org/10.1016/S0168-3659(00)00223-6>10.1016/S0168-3659(00)00223-6</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR75</td><td>BibChapter</td><td>Huang L, Viroonchatapan E. Introduction. In: Huang L, Hung M-C, Wagner E, ed.<Emphasis Type="Italic">Nonviral Vectors for Gene Therapy</Emphasis>. San Diego, CA: Academic Press; 1999:3&#8211;22.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1385/1592591396>10.1385/1592591396</a></td><td><b>CrossRef-Web</b></td>
<td>BookTitle</td><td>CrossRef</td></tr><tr><td>CR76</td><td>BibArticle</td><td>Mah C, Byrne BJ, Flotte TR. Virus-based gene delivery systems.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 2002;41:901&#8211;911.</td><td><a href=http://dx.doi.org/10.2165/00003088-200241120-00001>10.2165/00003088-200241120-00001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR77</td><td>BibArticle</td><td>Lotze MT, Kost TA. Viruses as gene delivery vectors: application to gene function, target validation, and assay development.<Emphasis Type="Italic">Cancer Gene Ther.</Emphasis> 2002;9:692&#8211;699.</td><td><a href=http://dx.doi.org/10.1038/sj.cgt.7700493>10.1038/sj.cgt.7700493</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR78</td><td>BibArticle</td><td>McTaggart S, Al-Rubeai M. Retroviral vectors for human gene delivery.<Emphasis Type="Italic">Biotechnol Adv.</Emphasis>. 2002;20:1&#8211;31.</td><td><a href=http://dx.doi.org/10.1016/S0734-9750(01)00087-8>10.1016/S0734-9750(01)00087-8</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR79</td><td>BibArticle</td><td>Galimi F, Verma IM. Opportunities for the use of lentiviral vectors in human gene therapy.<Emphasis Type="Italic">Curr Top Microbiol Immunol</Emphasis>. 2002;261:245&#8211;254.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1007/978-3-642-56114-6_13>10.1007/978-3-642-56114-6_13</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, Author_FamilyName_2, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR80</td><td>BibArticle</td><td>Martin KR, Klein RL, Quigley HA. Gene delivery to the eye using adeno-associated viral vectors.<Emphasis Type="Italic">Methods</Emphasis>. 2002;28(2):267&#8211;275.</td><td><a href=http://dx.doi.org/10.1016/S1046-2023(02)00232-3>10.1016/S1046-2023(02)00232-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR81</td><td>BibArticle</td><td>Lien Y-HH, Lai L-W. Gene therapy for renal disorders: what are the benefits for the elderly?.<Emphasis Type="Italic">Drugs Aging.</Emphasis>. 2002;19:553&#8211;560.</td><td><a href=http://dx.doi.org/10.2165/00002512-200219080-00001>10.2165/00002512-200219080-00001</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR82</td><td>BibArticle</td><td>Chamberlain JS. Gene therapy of muscular dystrophy.<Emphasis Type="Italic">Hum Mol Genet</Emphasis>. 2002;11:2355&#8211;2362.</td><td><a href=http://dx.doi.org/10.1093/hmg/11.20.2355>10.1093/hmg/11.20.2355</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR83</td><td>BibArticle</td><td>Wolf JK, Jenkins AD. Gene therapy for ovarian cancer (review).<Emphasis Type="Italic">Int J Oncol</Emphasis>. 2002;21:461&#8211;468.</td><td><a href=http://dx.doi.org/10.3892/ijo.21.3.461>10.3892/ijo.21.3.461</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Year, JournalTitle, ArticleTitle, Author_FamilyName_2, Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR84</td><td>BibArticle</td><td>Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases.<Emphasis Type="Italic">Drugs</Emphasis>. 2000;60:249&#8211;271.</td><td><a href=http://dx.doi.org/10.2165/00003495-200060020-00002>10.2165/00003495-200060020-00002</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR85</td><td>BibArticle</td><td>Lever AML. Gene therapy in the fight against AIDS.<Emphasis Type="Italic">Expert Opinion on Therapeutic Patents</Emphasis>. 1996;6:161&#8211;167.</td><td><a href=http://dx.doi.org/10.1517/13543776.6.2.161>10.1517/13543776.6.2.161</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR86</td><td>BibArticle</td><td>Zhao W, Kobayashi M, Hosokawa M, Seth P. Adenoviral vectors for cancer gene therapy.<Emphasis Type="Italic">Curr Genomics</Emphasis>. 2002;3:163&#8211;180.</td><td><a href=http://dx.doi.org/10.2174/1389202023350516>10.2174/1389202023350516</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR87</td><td>BibArticle</td><td>Hale SJ, Green NK. Viral approaches to cancer gene therapy.<Emphasis Type="Italic">Expert Opinion on Therapeutic Patents</Emphasis>. 2002;12:369&#8211;378.</td><td><a href=http://dx.doi.org/10.1517/13543776.12.3.369>10.1517/13543776.12.3.369</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR88</td><td>BibArticle</td><td>Garton KJ, Ferri N, Raines EW. Efficient expression of exogenous genes in primary vascular cells using IRES-based retroviral vectors.<Emphasis Type="Italic">Biotechniques</Emphasis>. 2002;32(4):830,832,834,836,838,840,842&#8211;843.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR89</td><td>BibArticle</td><td>Heider H, Verca SB, Rusconi S, Asmis R. Comparison of lipid-mediated and adenoviral gene transfer in human monocyte-derived macrophages and COS-7 cells.<Emphasis Type="Italic">Biotechniques</Emphasis>. 2000;28(2):260&#8211;265, 268&#8211;270.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR90</td><td>BibArticle</td><td>Kay MA, Glorioso JC, Naldini L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics.<Emphasis Type="Italic">Nat Med.</Emphasis> 2001;7:33&#8211;40.</td><td><a href=http://dx.doi.org/10.1038/83324>10.1038/83324</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR91</td><td>BibArticle</td><td>Favre D, Provost N, Blouin V, et al. Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle.<Emphasis Type="Italic">Mol Ther.</Emphasis> 2001;4:559&#8211;566.</td><td><a href=http://dx.doi.org/10.1006/mthe.2001.0494>10.1006/mthe.2001.0494</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR92</td><td>BibArticle</td><td>Timme TL, Hall SJ, Barrios R, Woo SLC, Aguilar-Cordova E, Thompson TC. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice.<Emphasis Type="Italic">Cancer Gene Ther</Emphasis>. 1998;5:74&#8211;82.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR93</td><td>BibArticle</td><td>Arruda VR, Fields PA, Milner R, et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males.<Emphasis Type="Italic">Mol Ther.</Emphasis> 2001;4:586&#8211;592.</td><td><a href=http://dx.doi.org/10.1006/mthe.2001.0491>10.1006/mthe.2001.0491</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR94</td><td>BibArticle</td><td>Tenenbaum L, Lehtonen E, Monahan PE. Evaluation of risks related to the use of adeno-associated virus-based vectors.<Emphasis Type="Italic">Curr Gene Ther</Emphasis>. 2003;3:545&#8211;565.</td><td><a href=http://dx.doi.org/10.2174/1566523034578131>10.2174/1566523034578131</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR95</td><td>BibArticle</td><td>Flotte TR, Laube BL. Gene therapy in cystic fibrosis.<Emphasis Type="Italic">Chest</Emphasis>. 2001;120(suppl 3):124S-131S.</td><td><a href=http://dx.doi.org/10.1378/chest.120.3_suppl.124S>10.1378/chest.120.3_suppl.124S</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR96</td><td>BibArticle</td><td>Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer.<Emphasis Type="Italic">Mol Genet Metab</Emphasis>. 2003;80(1&#8211;2):148&#8211;158.</td><td><a href=http://dx.doi.org/10.1016/j.ymgme.2003.08.016>10.1016/j.ymgme.2003.08.016</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR97</td><td>BibArticle</td><td>Owens RA. Second generation adeno-associated virus type 2-based gene therapy systems with the potential for preferential integration into AAVSI.<Emphasis Type="Italic">Curr Gene Ther</Emphasis>. 2002;2:145&#8211;159.</td><td><a href=http://dx.doi.org/10.2174/1566523024605627>10.2174/1566523024605627</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR98</td><td>BibArticle</td><td>Nyberg-Hoffman C, Aguilar-Cordova E. Instability of adenoviral vectors during transport and its implication for clinical studies.<Emphasis Type="Italic">Nat Med.</Emphasis> 1999;5:955&#8211;957.</td><td><a href=http://dx.doi.org/10.1038/11400>10.1038/11400</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR99</td><td>BibArticle</td><td>Cao B, Mytinger JR, Huard J. Adenovirus mediated gene transfer to skeletal muscle.<Emphasis Type="Italic">Microsc Res Tech</Emphasis>. 2002;58:45&#8211;51.</td><td><a href=http://dx.doi.org/10.1002/jemt.10116>10.1002/jemt.10116</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR100</td><td>BibArticle</td><td>Bachrach E, Pelegrin M, Piechaczyk M, Pedersen FS, Duch M. Efficient Gene Transfer into Spleen Cells of Newborn Mice by a Replication-Competent Retroviral Vector.<Emphasis Type="Italic">Virology</Emphasis>. 2002;293:328&#8211;334.</td><td><a href=http://dx.doi.org/10.1006/viro.2001.1284>10.1006/viro.2001.1284</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR101</td><td>BibArticle</td><td>Fattal E, Delattre J, Dubernet C, Couvreur P. Liposomes for the delivery of nucleotides and oligonucleotides.<Emphasis Type="Italic">S.T.P. Pharma Sciences</Emphasis>. 1999;9:383&#8211;390.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR102</td><td>BibArticle</td><td>Fattal E, Dubernet C, Couvreur P. Liposome-based formulations for the delivery of oligonucleotides.<Emphasis Type="Italic">S.T.P. Pharma Sciences</Emphasis>. 2001;11:31&#8211;44.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR103</td><td>BibArticle</td><td>Pedroso de Lima MC, Simoes S, Pires P, Faneca H, Duzgunes N. Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications.<Emphasis Type="Italic">Adv Drug Deliv Rev</Emphasis>. 2001;47(2&#8211;3):277&#8211;294.</td><td><a href=http://dx.doi.org/10.1016/S0169-409X(01)00110-7>10.1016/S0169-409X(01)00110-7</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR104</td><td>BibArticle</td><td>Hwang SJ, Davis ME. Cationic polymers for gene delivery: designs for overcoming barriers to systemic administration.<Emphasis Type="Italic">Curr Opin Mol Ther</Emphasis>. 2001;3:183&#8211;191.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR105</td><td>BibArticle</td><td>Lemkine GF, Demeneix BA. Polyethylenimines for in vivo gene delivery.<Emphasis Type="Italic">Curr Opin Mol Ther</Emphasis>. 2001;3:178&#8211;182.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR106</td><td>BibArticle</td><td>Lollo CP, Banaszezyk MG, Mullen PM, et al. Poly-L-lysine-based gene delivery systems: synthesis, purification, and application.<Emphasis Type="Italic">Methods Mol Med.</Emphasis> 2002;69:1&#8211;13.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1385/1-59259-141-8:001>10.1385/1-59259-141-8:001</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1</td><td>CrossRef</td></tr><tr><td>CR107</td><td>BibArticle</td><td>Borchard G. Chitosans for gene delivery.<Emphasis Type="Italic">Adv Drug Deliv Rev</Emphasis>. 2001;52:145&#8211;150.</td><td><a href=http://dx.doi.org/10.1016/S0169-409X(01)00198-3>10.1016/S0169-409X(01)00198-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR108</td><td>BibArticle</td><td>LeHoux JG, Grondin F. Some effects of chitosan on liver function in the rat.<Emphasis Type="Italic">Endocrinology</Emphasis>. 1993;132:1078&#8211;1084.</td><td><a href=http://dx.doi.org/10.1210/en.132.3.1078>10.1210/en.132.3.1078</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR109</td><td>BibArticle</td><td>Florea BI, Meaney C, Junginger HE, Borchard G. Transfection efficiency and toxicity of polyethylenimine in differentiated Calu-3 and non-differentiated COS-1 cell cultures.<Emphasis Type="Italic">AAPS Pharm Sci</Emphasis>. 2002;4(3):E12.</td><td><a href=http://dx.doi.org/10.1208/ps040312>10.1208/ps040312</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR110</td><td>BibArticle</td><td>Koping-Hoggard M, Tubulekas I, Guan H, et al. Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo.<Emphasis Type="Italic">Gene Ther</Emphasis>. 2001;8:1108&#8211;1121.</td><td><a href=http://dx.doi.org/10.1038/sj.gt.3301492>10.1038/sj.gt.3301492</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR111</td><td>BibArticle</td><td>Godbey WT, Mikos AG. Recent progress in gene delivery using non-viral transfer complexes.<Emphasis Type="Italic">J Control Release</Emphasis>. 2001;72(1&#8211;3):115&#8211;125.</td><td><a href=http://dx.doi.org/10.1016/S0168-3659(01)00267-X>10.1016/S0168-3659(01)00267-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR112</td><td>BibArticle</td><td>Petersen H, Fechner PM, Fischer D, Kissel T. Synthesis, characterization, and biocompatibility of polyethylenimine-graft-poly(ethylene glycol) block copolymers.<Emphasis Type="Italic">Macromolecules</Emphasis>. 2002;35:6867&#8211;6874.</td><td><a href=http://dx.doi.org/10.1021/ma012060a>10.1021/ma012060a</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR113</td><td>BibArticle</td><td>Leclercq F, Dubertret C, Pitard B, Scherman D, Herscovici J. Synthesis of glycosylated polyethylenimine with reduced toxicity and high transfecting efficiency.<Emphasis Type="Italic">Bioorg Med Chem Lett</Emphasis>. 2000;10:1233&#8211;1235.</td><td><a href=http://dx.doi.org/10.1016/S0960-894X(00)00195-5>10.1016/S0960-894X(00)00195-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR114</td><td>BibArticle</td><td>Akinc A, Langer R. Measuring the pH environment of DNA delivered using nonviral vectors: implications for lysosomal trafficking.<Emphasis Type="Italic">Biotechnol Bioeng</Emphasis>. 2002;78:503&#8211;508.</td><td><a href=http://dx.doi.org/10.1002/bit.20215>10.1002/bit.20215</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR115</td><td>BibArticle</td><td>Mumper RJ, Klakamp SL. Polymeric gene delivery systems for in vivo gene therapy.<Emphasis Type="Italic">Drug Targeting and Delivery</Emphasis>. 1999;10(Advanced Gene Delivery):143&#8211;173.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR116</td><td>BibArticle</td><td>Ward CM, Pechar M, Oupicky D, Ulbrich K, Seymour LW. Modification of pLL/DNA complexes with a multivalent hydrophilic polymer permits folate-mediated targeting in vitro and prolonged plasma circulation in vivo.<Emphasis Type="Italic">J Gene Med</Emphasis>. 2002;4:536&#8211;547.</td><td><a href=http://dx.doi.org/10.1002/jgm.296>10.1002/jgm.296</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR117</td><td>BibArticle</td><td>Jeong JH, Park TG. Poly(l-lysine)-g-poly(d,l-lactic-co-glycolic acid) micelles for low cytotoxic biodegradable gene delivery carriers.<Emphasis Type="Italic">J Control Release</Emphasis>. 2002;82:159&#8211;166.</td><td><a href=http://dx.doi.org/10.1016/S0168-3659(02)00131-1>10.1016/S0168-3659(02)00131-1</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR118</td><td>BibArticle</td><td>Wolfert MA, Seymour LW. Chloroquine and amphipathic peptide helixes show synergistic transfection in vitro.<Emphasis Type="Italic">Gene Ther</Emphasis>. 1998;5:409&#8211;414.</td><td><a href=http://dx.doi.org/10.1038/sj.gt.3300606>10.1038/sj.gt.3300606</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR119</td><td>BibArticle</td><td>Singla AK, Chawla M. Chitosan: some pharmaceutical and biological aspects-an update.<Emphasis Type="Italic">J Pharm Pharmacol</Emphasis>. 2001;53:1047&#8211;1067.</td><td><a href=http://dx.doi.org/10.1211/0022357011776441>10.1211/0022357011776441</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR120</td><td>BibArticle</td><td>Kawamata Y, Nagayama Y, Nakao K, et al. Receptor-independent augmentation of adenovirus-mediated gene transfer with chitosan in vitro.<Emphasis Type="Italic">Biomaterials</Emphasis>. 2002;23:4573&#8211;4579.</td><td><a href=http://dx.doi.org/10.1016/S0142-9612(02)00203-X>10.1016/S0142-9612(02)00203-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR121</td><td>BibArticle</td><td>Cui Z, Mumper RJ. Chitosan-based nanoparticles for topical genetic immunization.<Emphasis Type="Italic">J Control Release</Emphasis>. 2001;75:409&#8211;419.</td><td><a href=http://dx.doi.org/10.1016/S0168-3659(01)00407-2>10.1016/S0168-3659(01)00407-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR122</td><td>BibArticle</td><td>Roy K, Mao H-Q, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunological protection in a murine model of peanut allergy.<Emphasis Type="Italic">Nat Med</Emphasis>. 1999;5:387&#8211;391.</td><td><a href=http://dx.doi.org/10.1038/7385>10.1038/7385</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR123</td><td>BibArticle</td><td>Gitsov I, Lambrych KR. Dendrimers: synthesis and applications.<Emphasis Type="Italic">Microspheres, Microcapsules &amp; Liposomes</Emphasis>. 2002;5(Dendrimers, Assemblies, Nanocomposites):31&#8211;68.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR124</td><td>BibArticle</td><td>Eichman JD, Bielinska AU, Kukowska-Latallo JF, Baker JR, Jr. The use of PAMAM dendrimers in the efficient transfer of genetic material into cells.<Emphasis Type="Italic">Pharm Sci Technol Today</Emphasis>. 2000;3:232&#8211;245.</td><td><a href=http://dx.doi.org/10.1016/S1461-5347(00)00273-X>10.1016/S1461-5347(00)00273-X</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR125</td><td>BibArticle</td><td>Zinselmeyer BH, Mackay SP, Schatzlein AG, Uchegbu IF. The lower-generation polypropylenimine dendrimers are effective gene-transfer agents.<Emphasis Type="Italic">Pharm Res</Emphasis>. 2002;19:960&#8211;967.</td><td><a href=http://dx.doi.org/10.1023/A:1016458104359>10.1023/A:1016458104359</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR126</td><td>BibArticle</td><td>Yoo H, Juliano RL. Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers.<Emphasis Type="Italic">Nucleic Acids Res</Emphasis>. 2000;28:4225&#8211;4231.</td><td><a href=http://dx.doi.org/10.1093/nar/28.21.4225>10.1093/nar/28.21.4225</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR127</td><td>BibArticle</td><td>Tejada-Berges T, Granai CO, Gordinier M, Gajewski W. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer.<Emphasis Type="Italic">Expert Rev Anticancer Ther</Emphasis>. 2002;2:143&#8211;150.</td><td><a href=http://dx.doi.org/10.1586/14737140.2.2.143>10.1586/14737140.2.2.143</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR128</td><td>BibChapter</td><td>Marshall J, Yew NS, Eastman SJ, Jiang C, Scheule RK, Cheng SH. Cationic lipid-mediated gene delivery to the airways. In: Wagner E, ed.<Emphasis Type="Italic">Nonviral Vectors for Gene Therapy</Emphasis>. San Diego, CA: Academic Press; 1999;39&#8211;68.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1385/1592591396>10.1385/1592591396</a></td><td><b>CrossRef-Web</b></td>
<td>BookTitle</td><td>CrossRef</td></tr><tr><td>CR129</td><td>BibArticle</td><td>Felgner JH, Kumar R, Sridhar CN, et al. Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 1994;269:2550&#8211;2561.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR130</td><td>BibArticle</td><td>Hofland HEJ, Shephard L, Sullivan SM. Formation of stable cationic lipid/DNA complexes for gene transfer.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1996;93:7305&#8211;7309.</td><td><a href=http://dx.doi.org/10.1073/pnas.93.14.7305>10.1073/pnas.93.14.7305</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR131</td><td>BibArticle</td><td>Kang S-H, Zirbes EL, Kole R. Delivery of antisense oligonucleotides and plasmid DNA with various carrier agents.<Emphasis Type="Italic">Antisense Nucleic Acid Drug Dev</Emphasis>. 1999;9:497&#8211;505.</td><td><a href=http://dx.doi.org/10.1089/oli.1.1999.9.497>10.1089/oli.1.1999.9.497</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>VolumeID, Year, FirstPage, Author_FamilyName_2, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR132</td><td>BibArticle</td><td>Lappalainen K, Jaaskelainen I, Syrjanen K, Urtti A, Syrjanen S. Comparison of cell proliferation and toxicity assays using two cationic liposomes.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1994;11:1127&#8211;1131.</td><td><a href=http://dx.doi.org/10.1023/A:1018932714745>10.1023/A:1018932714745</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR133</td><td>BibArticle</td><td>Patil SD, Rhodes DG, Burgess DJ. Anionic liposomal delivery system for DNA transfection.<Emphasis Type="Italic">The AAPS Journal</Emphasis>. 2004;6:E29.</td><td><a href=http://dx.doi.org/10.1208/aapsj060429>10.1208/aapsj060429</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR134</td><td>BibArticle</td><td>Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes.<Emphasis Type="Italic">Pharm Res</Emphasis>. 2000;17:521&#8211;525.</td><td><a href=http://dx.doi.org/10.1023/A:1007504613351>10.1023/A:1007504613351</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR135</td><td>BibArticle</td><td>Filion MC, Phillips NC. Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells.<Emphasis Type="Italic">Biochim Biophys Acta</Emphasis>. 1997;1329:345&#8211;356.</td><td><a href=http://dx.doi.org/10.1016/S0005-2736(97)00126-0>10.1016/S0005-2736(97)00126-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR136</td><td>BibArticle</td><td>Freimark BD, Blezinger HP, Florack VJ, et al. Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes.<Emphasis Type="Italic">J Immunol</Emphasis>. 1998;160:4580&#8211;4586.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR137</td><td>BibArticle</td><td>Lee H, Williams SKR, Allison SD, Anchordoquy TJ. Analysis of self-assembled cationic lipid-DNA gene carrier complexes using flow field-flow fractionation and light scattering.<Emphasis Type="Italic">Anal Chem</Emphasis>. 2001;73:837&#8211;843.</td><td><a href=http://dx.doi.org/10.1021/ac000831n>10.1021/ac000831n</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR138</td><td>BibArticle</td><td>Audouy S, Molema G, De Leij L, Hoekstra D. Serum as a modulator of lipoplex-mediated gene transfection: dependence of amphiphile, cell type and complex stability.<Emphasis Type="Italic">J Gene Med</Emphasis>. 2000;2:465&#8211;476.</td><td><a href=http://dx.doi.org/10.1002/1521-2254(200011/12)2:6&lt;465::AID-JGM141&gt;3.0.CO;2-Z>10.1002/1521-2254(200011/12)2:6&lt;465::AID-JGM141&gt;3.0.CO;2-Z</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR139</td><td>BibArticle</td><td>Liu F, Qi H, Huang L, Liu D. Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration.<Emphasis Type="Italic">Gene Ther</Emphasis>. 1997;4:517&#8211;523.</td><td><a href=http://dx.doi.org/10.1038/sj.gt.3300424>10.1038/sj.gt.3300424</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR140</td><td>BibArticle</td><td>Wheeler CJ, Felgner PL, Tsai YJ, et al. A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1996;93:11454&#8211;11459.</td><td><a href=http://dx.doi.org/10.1073/pnas.93.21.11454>10.1073/pnas.93.21.11454</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR141</td><td>BibArticle</td><td>Fillion P, Desjardins A, Sayasith K, Lagace J. Encapsulation of DNA in negatively charged liposomes and inhibition of bacterial gene expression with fluid liposome-encapsulated antisense oligonucleotides.<Emphasis Type="Italic">Biochim Biophys Acta</Emphasis>. 2001;1515:44&#8211;54.</td><td><a href=http://dx.doi.org/10.1016/S0005-2736(01)00392-3>10.1016/S0005-2736(01)00392-3</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR142</td><td>BibArticle</td><td>Lakkaraju A, Dubinsky JM, Low WC, Rahman Y-E. Neurons are protected from excitotoxic death by p53 antisense oligonucleotides delivered in anionic liposomes.<Emphasis Type="Italic">J Biol Chem</Emphasis>. 2001;276:32000&#8211;32007.</td><td><a href=http://dx.doi.org/10.1074/jbc.M100138200>10.1074/jbc.M100138200</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR143</td><td>BibArticle</td><td>Patil SD, Rhodes DG. Conformation of oligodeoxynucleotides associated with anionic liposomes.<Emphasis Type="Italic">Nucleic Acids Res</Emphasis>. 2000;28:4125&#8211;4129.</td><td><a href=http://dx.doi.org/10.1093/nar/28.21.4125>10.1093/nar/28.21.4125</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR144</td><td>BibUnstructured</td><td><aug><span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Patil</span> <span style='background:#DDDDDD'>SD</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Rhodes</span> <span style='background:#DDDDDD'>DG</span></span>, <span style='border:dotted windowtext 1.0pt;padding:0pt'><span style='background:#BCBCBC'>Burgess</span> <span style='background:#DDDDDD'>DJ</span></span></aug>. Biophysical characterization of anionic <i>lipoplexesBiochim Biophys Acta.-Biomembranes</i>. 2005; In Press.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR145</td><td>BibArticle</td><td>Lee RJ, Huang L. Lipidic vector systems for gene transfer.<Emphasis Type="Italic">Crit Rev Ther Drug Carrier Syst</Emphasis>. 1997;14:173&#8211;206.</td><td><a href=http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v14.i2.30>10.1615/CritRevTherDrugCarrierSyst.v14.i2.30</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>JournalTitle, VolumeID, Year, Author_FamilyName_2, Author_FamilyName_1, ArticleTitle</td><td>CrossRef</td></tr><tr><td>CR146</td><td>BibArticle</td><td>Guo W, Gosselin MA, Lee RJ. Characterization of a novel diolein-based LPDII vector for gene delivery.<Emphasis Type="Italic">J Control Release</Emphasis>. 2002;83:121&#8211;132.</td><td><a href=http://dx.doi.org/10.1016/S0168-3659(02)00167-0>10.1016/S0168-3659(02)00167-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR147</td><td>BibArticle</td><td>Perrie Y, Gregoriadis G. Liposome-entrapped plasmid DNA: characterization studies.<Emphasis Type="Italic">Biochim Biophys Acta</Emphasis>. 2000;1475:125&#8211;132.</td><td>&nbsp;</td><td><a href=http://dx.doi.org/10.1016/S0304-4165(00)00055-6>10.1016/S0304-4165(00)00055-6</a></td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, FirstPage, VolumeID, Year</td><td>CrossRef</td></tr><tr><td>CR148</td><td>BibArticle</td><td>Venugopalan P, Jain S, Sankar S, Singh P, Rawat A, Vyas SP. pH-Sensitive liposomes: mechanism of triggered release to drug and gene delivery prospects.<Emphasis Type="Italic">Pharmazie</Emphasis>. 2002;57:659&#8211;671.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR149</td><td>BibArticle</td><td>Maclean AL, Symonds G, Ward R. Immunoliposomes as targeted delivery vehicles for cancer therapeutics (Review).<Emphasis Type="Italic">Int J Oncol</Emphasis>. 1997;11:325&#8211;332.</td><td><a href=http://dx.doi.org/10.3892/ijo.11.2.325>10.3892/ijo.11.2.325</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_2, Author_FamilyName_1, ArticleTitle, Year, JournalTitle</td><td>CrossRef</td></tr><tr><td>CR150</td><td>BibArticle</td><td>Legendre JY, Szoka FC Jr. Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: comparison with cationic liposomes.<Emphasis Type="Italic">Pharm Res</Emphasis>. 1992;9:1235&#8211;1242.</td><td><a href=http://dx.doi.org/10.1023/A:1015836829670>10.1023/A:1015836829670</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR151</td><td>BibArticle</td><td>Reddy JA, Low PS. Enhanced folate receptor mediated gene therapy using a novel pH-sensitive lipid formulation.<Emphasis Type="Italic">J Control Release</Emphasis>. 2000;64(1&#8211;3):27&#8211;37.</td><td><a href=http://dx.doi.org/10.1016/S0168-3659(99)00135-2>10.1016/S0168-3659(99)00135-2</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR152</td><td>BibArticle</td><td>Sviridov YV, Zhdanov RI, Podobed OV, Tsvetkova TA, Konstantinov I, Bogdanenko EV. The LacZ gene transfer into L929 cells and [14C]-DNA tissue distribution following intraperitoneal administration of new pH-sensitive lipoplexes in mice.<Emphasis Type="Italic">Cytobios</Emphasis>. 2001;106:(suppl 1), 7&#8211;14.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR153</td><td>BibArticle</td><td>Xu L, Huang C-C, Huang W, et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.<Emphasis Type="Italic">Mol Cancer Ther</Emphasis>. 2002;1:337&#8211;346.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR154</td><td>BibArticle</td><td>Shi N, Zhang Y, Zhu C, Boado RJ, Pardridge WM. Brain-specific expression of an exogenous gene after IV administration.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2001;98:12754&#8211;12759.</td><td><a href=http://dx.doi.org/10.1073/pnas.221450098>10.1073/pnas.221450098</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR155</td><td>BibArticle</td><td>Khaw BA, da Silva J, Vural I, Narula J, Torchilin VP. Intracytoplasmic gene delivery for in vitro transfection with cytoskeleton-specific immunoliposomes.<Emphasis Type="Italic">J Control Release</Emphasis>. 2001;75(1&#8211;2):199&#8211;210.</td><td><a href=http://dx.doi.org/10.1016/S0168-3659(01)00364-9>10.1016/S0168-3659(01)00364-9</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR156</td><td>BibArticle</td><td>Krauss WC, Park JW, Kirpotin DB, Hong K, Benz CC. Emerging antibody-based HER2 (ErbB-2/neu) therapeutics.<Emphasis Type="Italic">Breast Disease</Emphasis>. 2000;11:113&#8211;124.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR157</td><td>BibArticle</td><td>Mannisto M, Vanderkerken S, Toncheva V, et al. Structure-activity relationships of poly(l-lysines): effects of pegylation and molecular shape on physicochemical and biological properties in gene delivery.<Emphasis Type="Italic">J Control Release</Emphasis>. 2002;83:169&#8211;182.</td><td><a href=http://dx.doi.org/10.1016/S0168-3659(02)00178-5>10.1016/S0168-3659(02)00178-5</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>